FDA proposes new guidelines to expedite biosimilar drug approvals, aiming to increase competition, lower prices, and improve patient access to biologic treatments.
FDA proposes new guidelines to expedite biosimilar drug approvals, aiming to increase competition, lower prices, and improve patient access to biologic treatments.